Technical Analysis for GPCR - Structure Therapeutics Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| A | 50.42 | 34.56% | 12.95 |
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | N/A | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Gilligan's Island Sell Setup | Bearish Swing Setup | 0.00% | |
| New 52 Week Closing High | Bullish | 0.00% | |
| New Uptrend | Bullish | 0.00% | |
| Expansion Breakout | Bullish Swing Setup | 0.00% | |
| Pocket Pivot | Bullish Swing Setup | 0.00% | |
| Volume Surge | Other | 0.00% | |
| Wide Range Bar | Range Expansion | 0.00% | |
| New 52 Week High | Strength | 0.00% | |
| Parabolic Rise | Strength | 0.00% | |
| Upper Bollinger Band Walk | Strength | 0.00% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| 60 Minute Opening Range Breakdown | about 11 hours ago |
| Gapped Up (Full) | about 13 hours ago |
| Rose Above Previous Day's High | about 13 hours ago |
| New 52 Week High | about 13 hours ago |
| Rose Above Upper Bollinger Band | about 13 hours ago |
Get this analysis on your stocks daily!
- Earnings date: 08/30/2023
Structure Therapeutics Inc. Description
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist, targeting apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension; and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was founded in 2016 and is headquartered in South San Francisco, California.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Life Sciences Biology Molecular Biology Obesity Pulmonary Arterial Hypertension Signal Transduction Chronic Disease Diabetes Mellitus Idiopathic Pulmonary Fibrosis Biochemistry Glucagon Receptor
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 65.51 |
| 52 Week Low | 20.8001 |
| Average Volume | 736,172 |
| 200-Day Moving Average | 0.00 |
| 50-Day Moving Average | 31.57 |
| 20-Day Moving Average | 33.01 |
| 10-Day Moving Average | 36.48 |
| Average True Range | 3.99 |
| RSI (14) | 83.33 |
| ADX | 26.92 |
| +DI | 63.35 |
| -DI | 6.71 |
| Chandelier Exit (Long, 3 ATRs) | 53.53 |
| Chandelier Exit (Short, 3 ATRs) | 39.23 |
| Upper Bollinger Bands | 42.90 |
| Lower Bollinger Band | 23.12 |
| Percent B (%b) | 1.38 |
| BandWidth | 59.91 |
| MACD Line | 2.73 |
| MACD Signal Line | 1.34 |
| MACD Histogram | 1.3895 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 75.86 | ||||
| Resistance 3 (R3) | 78.06 | 71.79 | 71.62 | ||
| Resistance 2 (R2) | 71.79 | 65.31 | 70.68 | 70.21 | |
| Resistance 1 (R1) | 61.10 | 61.31 | 57.97 | 58.90 | 68.79 |
| Pivot Point | 54.83 | 54.83 | 53.26 | 53.73 | 54.83 |
| Support 1 (S1) | 44.14 | 48.35 | 41.01 | 41.94 | 32.05 |
| Support 2 (S2) | 37.87 | 44.35 | 36.77 | 30.63 | |
| Support 3 (S3) | 27.18 | 37.87 | 29.22 | ||
| Support 4 (S4) | 24.98 |
